COVID-19 Funding Opportunities
New COVID-19 funding opportunities relevant to UC Berkeley researchers will be added as they are released by federal and state funding agencies, foundations, non-profits and industry partners. Entries are sorted in reverse chronological order. Please use the filters, sorting and search tools below to find the opportunities most useful to you. Suggest additional entries by emailing email@example.com.
If you are looking for help with large-scale state and federal proposals, or restricted and emerging opportunities, please contact the Berkeley Research Development Office (BRDO). Foundation Relations and Corporate Philanthropy provides support for your proposals to foundations and some corporate sponsors. All proposals for sponsored projects funded by government or non-profit sponsors are reviewed and authorized for submission by the Sponsored Projects Office (SPO). SPO offers an expedited review process for all COVID-19 related proposals.
|Sponsor||Grant/Award Title||Description||Funding area(s)||Amount||Sponsor Deadline||Posted on||NID||Special Notes|
|Shurl and Kay Curci Foundation and IGI||SKCF Faculty Scholar Award||
The Innovative Genomics Institute (IGI), a joint partnership between UC Berkeley and UC San Francisco, is currently soliciting applications for The Shurl & Kay Curci Foundation Faculty Scholars Program. This program is designed for early career faculty whose research and expertise focus on biomedicine and agricultural applications related to human health and wellness, aligned with the IGI’s vision in which genome engineering innovations benefit humanity.
One selected candidate will receive a total $179K award to provide research support over two years in the field of genetic engineering, including related to genome editing, next generation tools, transcriptional regulation, epigenetics, DNA repair, delivery, screening or imaging.
|Epidemiology & Public Health; Life Sciences||$179,000||24537|
|US Patent and Trade Office (USPTO)||COVID-19 Prioritized Examination Pilot Program and Patents 4 Partnerships||
The USPTO will grant qualified requests for prioritized examination without payment of certain fees associated with prioritized examination for applicants that qualify for small or micro entity status. The COVID-19 Prioritized Examination Pilot Program will accept requests for prioritized examination beginning July 13, 2020 until such time as the USPTO has accepted a total of 500 requests. The USPTO may extend the pilot program (with or without modifications) or terminate it depending on the workload and resources needed to administer the program, feedback from the public, and the effectiveness of the program.
Patents 4 Partnerships is a new online marketplace for patent owners to list patents and published applications that are available for licensing in fields that address COVID-19. The goal is to better connect in-demand intellectual property with industries interested in scaling the ideas.
|Mercatus Center||COVID-19 Response: A Call for Ideas||
The Mercatus Center, building on its COVID-19 policy brief series, welcomes proposals for policy briefs, working papers, and articles that address the next round of challenges facing the United States and other countries in the response to the pandemic. See the solicitation for the specific questions of interest in the topics of restarting and reopening, institutional challenges, health and science policy, economic and regulatory policy, and monetary policy.
|Behavior & Psychology; Community & Social Services; Data Science, AI & Computing; Epidemiology & Public Health; Humanities; Life Sciences; Policy, Economics & Labor||24471||Proposals will be reviewed on a rolling basis.|
|Draper Richards Kaplan Foundation||COVID-19 Urgent Response Initiative||
DRK is ready to find, fund, and support the people and ideas that are tackling the most acute and time-critical social problems caused by the Covid-19 pandemic right now. We want to help jumpstart projects that can realistically deploy within 30 days. We are best positioned to help work on the social problems caused by the pandemic versus direct mitigation via medical and scientific efforts. We will filter potential investments through the lens of urgency: Can this make large impact at scale? Can it be deployed quickly? And can DRK be catalytic in making that happen?
|Behavior & Psychology; Community & Social Services; Data Science, AI & Computing; Engineering; Humanities; Policy, Economics & Labor; Instruction||Anticipated Range $50K-$100K||24469|
|NIH NCI-NIAID||Serological Sciences Network for SARS-CoV-2||
The NCI and NIAID have published a Notice of Intent (NOI) to publish a Funding Opportunity Announcement (FOA) within the coming weeks for research in Coronavirus Serology Testing and Serological Sciences. The Frederick National Lab (FNL) Serology Lab would serve as the core lab of the network, mainly validating serological tests for SARS-CoV-2, while the network will also include:
Capacity Building Centers will focus on developing and expanding serological testing capacity and practices in the community. NCI anticipates awarding 4-8 academic and/or private sector organizations with funding up to $3M/year for each site for up to five years.
Serological Centers of Excellence (U54 mechanism; 4-8 centers up to $1.5M/year) and Serological Sciences Projects (U01 mechanism; 4-6 investigators up to $500K/year) will be funded to understand the mechanisms driving serological, humoral, and cellular immune responses to SARS-CoV-2 viral infection to inform the development of novel serological tests.
There will be a preference for a cancer relevant component when funding the centers of excellence and the serological sciences projects.
|Epidemiology & Public Health; Life Sciences||$500,000 to $3,000,000 per year depending on funding mechanism||24459|
|CETF and Rockefeller Philanthropy Advisors||COVID-19 Early Treatment Fund (CETF)||
The COVID-19 Early Treatment Fund (CETF) is targeting early-stage COVID infections in outpatients — as opposed to hospitalized, critically ill patients — with the aim of preventing disease progression to the severe and often fatal stage seen in 20 percent of cases. We will be funding initiatives that focus on treating outpatients to prevent hospitalization. CETF is narrowly focused on ensuring that outpatient trials for four drugs are successful (Peginterferon lambda, Favipiravir, Camostate mesylate, and Remdesivir). That means we’ll provide funding, help improve study protocols, find ways to manufacture drugs in short supply and do whatever it takes to move these medicines forward. Please share your contact information so that we can follow up to share more details and further discuss this funding opportunity. We primarily fund phase 1b/2a outpatient clinical trials that cost $1 million or less but will also consider earlier stage projects.
|Epidemiology & Public Health; Life Sciences||Up to $1M||24444|
|Economic Development Administration (EDA)||EDA CARES Act Recovery Assistance||
The Coronavirus Aid, Relief, and Economic Security (CARES) Act provides the EDA with $1.5 billion for economic development assistance programs to help communities prevent, prepare for, and respond to coronavirus. EDA CARES Act Recovery Assistance provides a wide-range of financial assistance to communities and regions as they respond to and recover from the impacts of the pandemic. This includes: 1) Planning and Technical Assistance, 2) Construction of Infrastructure and Other Economic Development Projects, 3) Innovation Grants, and 4) Capitalization and Recapitalization of Revolving Loan Funds. Check that the proposed project fits the scope with the EDA regional office; applications reviewed on rolling basis.
|Community & Social Services; Policy, Economics & Labor||Typically up to $1,000,000||24445|
|Institute of Museum and Library Services (IMLS)||CARES Act Grants for Museums and Libraries||
The goal of the FY2020 IMLS CARES Act Grants for Museums and Libraries program is to support the role of museums and libraries in responding to the coronavirus pandemic. Projects may focus on preserving jobs, training staff, addressing the digital divide, planning for reopening, or providing technical support and capacity building for digital inclusion and engagement. Applicants are encouraged to prioritize services for high-need communities.
|Community & Social Services; Instruction||$25,000-$500,000||24446|
|Spencer Foundation||Research Grants on Education: COVID-19 Related Special Grant Cycle||
The COVID-19 Related Research Grants support education research projects that will contribute to understanding the rapid shifts in education in this time of crisis and change. We are especially interested in supporting two primary categories of projects. First, we are interested in supporting studies that aim to understand and disrupt the reproduction and deepening of educational inequality caused by the COVID-19 crisis. Second, we also recognize that in times of great disruption and change, there may be opportunities to remake and imagine anew forms of equitable education. Thus, we are also interested in research projects that are working to reimagine educational opportunities in these times.
|Behavior & Psychology; Community & Social Services; Humanities; Policy, Economics & Labor; Instruction||Up to $50K||24415|
|Booz Hamilton Foundation||Innovation Fund||
The goal of the fund is to surface the best solutions for addressing the social issues created by COVID-19 and empower the people and organizations behind those solutions to drive their development and implementation. The Foundation is specifically interested in solutions and projects that will build lasting community resilience through protecting vulnerable populations and frontline workers or providing for the safe return to work.
|Community & Social Services; Epidemiology & Public Health; Policy, Economics & Labor||Up to $100,000||24376|
|American Lung Association||COVID-19 and Emerging Respiratory Viruses Research Award||
We are looking for proposals to advance research against emerging respiratory pathogens like SARS-CoV-2. All research must directly be related to COVID-19 or other viral respiratory threats that may arise in the future. The Lung Association is interested in applications that address the following types of clinical, basic, translational, and population health questions: • A new understanding of the basic biology of respiratory viruses that could lead to better treatment and prevention • Development of novel therapeutics and vaccines • Understanding host factors that alter response to these infections • Understanding individual, regional, or social factors increasing or decreasing community spread of COVID-19 and other respiratory viruses • Case tracking and epidemiological approaches to understanding COVID-19 and other respiratory viruses
|Epidemiology & Public Health; Life Sciences||Up to $100,000||24369|
|NIH NIBIB Point-of-Care Technologies Research Network (POCTRN)||Rapid Acceleration of Diagnostics (RADx): Fast-Track Program for COVID-19 Test Development and Distribution||
NIBIB is providing substantial support to accelerate the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to clinical laboratory tests, that can directly detect SARS-CoV-2, the virus that causes COVID-19. NIBIB will support the full range of product development including commercialization and product distribution. RADx will support novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches. RADx is structured to deliver innovative testing strategies to the public as soon as late summer 2020 and is an accelerated and comprehensive multi-pronged effort by NIH to make SARS-CoV-2 testing readily available to every American. Proposal being reviewed on a rolling basis.
|Epidemiology & Public Health; Life Sciences||Phase 0 $25,000; Phase 1 $500,000; Phase 2 tens of millions expected||24359|
|NIH-NIAID||Emergency Awards: Rapid Investigation of SARS-CoV-2 and COVID-19 (R01 Clinical Trial Not Allowed) (PAR-20-178)||
Rapid R01 opportunity to provide an expedited funding mechanism for research on SARS-CoV-2 and COVID-19. See area of interest described for the related R21 opportunity (PAR-20-177). Choose whichever funding mechanism is most appropriate (R21 or R01) for your proposed research. Typically funds available up to $500,000; must contact PO in advance if requested amount will be greater than $500k.
|Epidemiology & Public Health; Life Sciences||Typically up to $500,000||24358|
|NIH-NIAID||Emergency Awards: Rapid Investigation of SARS-CoV-2 and COVID-19 (R21 Clinical Trial Not Allowed) (PAR-20-177)||
Rapid R21 opportunity to provide an expedited funding mechanism for research on SARS-CoV-2 and COVID-19. Transmission characteristics and the associated morbidity and mortality, viral pathogenesis, host immunity, natural history, and host range are currently poorly understood. There is an urgent public health need to better understand SARS-CoV-2/COVID-19, particularly to improve understanding of fundamental virology, immunology, and the development of animal models, reagents, and medical countermeasures and to share findings quickly and broadly. Applications will be handled on an expedited review and award basis to meet the goals of this program.
|Epidemiology & Public Health; Life Sciences||Up to $275,000||24357|
|Microsoft||COVID-19 Research Accelerator Program||
This grant program provides Azure cloud and High-Performance Computing capabilities. Our team of AI for Health data science experts, whose mission is to improve the health of people and communities worldwide, is also open to collaborations with COVID-19 researchers as they tackle this critical challenge. More broadly, Microsoft’s research scientists across the world, spanning computer science, biology, medicine, and public health, will also be available to provide advice and collaborate per mutual interest.
|Data Science, AI & Computing||24343|
|Social Sciences Research Council||New Interdisciplinary Projects in the Social Sciences||
Convening researchers of different backgrounds, disciplines, and institutions, the New Interdisciplinary Projects in the Social Sciences initiative acts as a catalyst for dialogue and collaboration that produces creative scholarship and builds fresh ties within the social sciences, while connecting them more robustly to work in the natural sciences and humanities. New Interdisciplinary Projects in the Social Sciences working groups may be composed of any cross-disciplinary arrangement of social scientists and other researchers.
Proposals for interdisciplinary research projects advancing understanding of the human, social, political, and ethical dimensions of Covid-19 are encouraged.
|Behavior & Psychology; Community & Social Services; Policy, Economics & Labor||Up to $50,000||24302|
|Alianza UCMX and InnovaUNAM||Special Call for Binational Collaborative Projects addressing COVID-19||
InnovaUNAM of the National Autonomous University of Mexico (UNAM) and Alianza UCMX of the University of California (UC) in collaboration with the Ministry of Foreign Affairs of Mexico, announced a special funding opportunity to support UNAM-UC collaborative innovation, product development, and applied research that aims to mitigate health, social, and economic impacts of the COVID-19 pandemic. See solicitation for specific priority areas within biomedical research, health systems, and social/economic consequences. First stage funding: $10,000 USD split equally between UC and UNAM partners. Second stage: Teams funded in the first round may request a second tranche of funding up to $25,000 USD to continue their work. Projects will be funded on a rolling basis until the May 30, 2020 deadline, subject to availability of funds.
|Community & Social Services; Data Science, AI & Computing; Engineering; Epidemiology & Public Health; Life Sciences; Policy, Economics & Labor||$10,000 for first stage; $25,000 for second stage||24288|
|DARPA||COVID-19 + DARPA||
4/23/20 funding update: $113 million is being reprogrammed from the Defense Health Program to DARPA's Biological Technologies Office (BTO), Defense Sciences Office (DSO), and Information Innovation Office (I2O) to address efforts relevant to the COVID-19 response. These efforts include deploying Artificial Intelligence (AI)-based models to screen for Food and Drug Administration (FDA)-approved therapeutics that may be able to treat COVID-19, running trials to test a COVID-19 RNA vaccine, developing capabilities to detect and screen environments for the airborne COVID-19 virus, and addressing supply chain vulnerabilities to develop U.S.- based production capabilities for pharmaceuticals needed to treat COVID-19, among others. Some of the activities described in the reprogramming are aligned with ongoing efforts at DARPA; it is unclear if this funding will be used to start any new efforts.
4/8/20: DARPA is encouraging researchers to submit COVID-19 related proposals through its standard Broad Agency Announcement (BAA) funding mechanism in the Biological Technologies Office or Defense Sciences Office. These BAA proposals are continuously open and reviewed.
|Behavior & Psychology; Data Science, AI & Computing; Engineering; Epidemiology & Public Health; Life Sciences||24093|
|DOD-Army||Pre-Announcement: Potential Request for Project Proposals (RPP) for development of prototypes to combat the coronavirus||
4/23/20 Update: MTEC anticipates potential upcoming solicitations in the following areas: 1) Point-of-care diagnostics to rapidly identify infected individuals, and 2) Predictive analytics that can forecast potential hot spots and empower decision makers' response actions
4/7/20: The Army's Medical Technology Enterprise Consortium (MTEC) has posted an announcement of the possibility of RPPs to rapidly accelerate development of technology to detect exposure, prevent, contain and treat COVID-19 and future emerging threats in the following areas:
1) Point-of-care diagnostic that provides rapid and accurate determination on exposure to COVID-19.
2) Prophylactic(s)/Therapeutic(s) that can prevent and/or treat in a rapid manner (few hours to 2 days) potentially in a non-hospital environment. Repurposing FDA-approved drugs/biologics for prevention/treatment of COVID-19 or testing of drugs/biologics that have already demonstrated safety in humans for the prevention/treatment of COVID-19 are preferred.
3) Disease predictive modeling that provides early warning through data capture from several different streams of data to include social media and artificial intelligence (AI) parameter decision tools that would provide actionable information to medical service providers and command structures.
4) Patient monitoring, tracking, and management system for in-home or non-hospital environment patient tele-health services to include interface into the Cerner electronic health record.
|Data Science, AI & Computing; Engineering; Epidemiology & Public Health; Life Sciences||24081|
|EdTech Hub, mEducation Alliance, Global Innovation Exchange (GIE)||Call for ideas for EdTech responses to coronavirus||
The EdTech Hub, mEducation Alliance, and Global Innovation Exchange (GIE) are launching a call for tech-focused ideas to respond to the learning emergency caused by COVID-19 school closures in low- and middle-income countries. Selected applicants will be invited to virtual EdTech Pitch Days with a global network of potential funders, support in adapting and scaling in response to COVID-19, and connections for onward collaboration and funding. See link for priority needs areas. Several evaluation rounds expected, with successful applicants notified by May 1, May 15, and May 29, 2020.
|Behavior & Psychology; Community & Social Services; Instruction||24276|
|NIH-NCATS||Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions and Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Award to Address COVID-19 Public Health Needs (NOT-TR-20-028)||
The National Center for Advancing Translational Sciences NCATS is soliciting applications for Administrative Supplements and Emergency Competitive Revisions from current Clinical and Translational Science Award (CTSA) UL1 and U24 award recipients. See link for eligible program details. Applications accepted on a rolling basis through Nov. 10, 2020
|Epidemiology & Public Health; Life Sciences||24275|
|DOD Defense Logistics Agency (DLA)||Request for Information (RFI) pertaining to Medical PPE in response to COVID-19 (SPE2DS-20-R-COVID19)||
Defense Logistics Agency (DLA) Troop Support Medical Directorate is conducting market research to determine industry capabilities for providing Medical based Personal Protective Equipment (PPE) against COVID-19. The primary purpose of this RFI is to identify near-term specific products, potential sources, and availability and/or challenges to meeting Medical PPE requirements to protect against COVID-19. DLA also seeks to identify alternatives or additional PPE items necessary to protect against viral contamination of COVID-19. DLA urges companies that can provide the above items to respond even after the new due date. Respondents are asked to provide either a technical data package for the item(s) or website links with detailed information on the product.
|Engineering; Epidemiology & Public Health||24269|
|Patient-Centered Outcomes Research Institute (PCORI)||COVID-19-Related Enhancements to Existing PCORI-Funded Projects||
Rooted in its mission to help people make informed healthcare decisions and improve healthcare delivery and outcomes, PCORI is poised to support work to provide answers to the challenging COVID-19 related dilemmas facing patients, caregivers, providers, health systems, and policymakers through targeted investments in extending our Research, Engagement Awards, and Dissemination and Implementation activities. Only PCORI-funded principal investigators with active research project funding contracts are eligible to submit a proposal in response to this announcement. Applications will be considered on a rolling basis.
|Community & Social Services; Epidemiology & Public Health||Up to $500,000||24237|
|USDA-NIFA||AFRI Competitive Grants Program update: Rapid Response to Novel Coronavirus Impacts Across Food and Agricultural Systems||
Update to the Agriculture and Food Research Initiative (AFRI) Competitive Grants Program with new program area priority for responding to Coronavirus. This funding track will support two-year research, extension, and integration projects of up to $1 million to develop and deploy “rapid, reliable, and readily adoptable strategies across the food and agriculture enterprise” that ensure the safety and accessibility of a nutritious food supply. Proposals should be interdisciplinary and focus on one or more of the following priority areas: Health and Security of Livestock; Well-being of Farm, Food Service Providers, and Rural Americans; Economic Security; and Food Safety. Proposals should explicitly highlight how the activities would directly address urgent stakeholder needs relating to COVID-19. Additionally, AFRI encourages proposals from or collaborations with minority serving institutions.
|Data Science, AI & Computing; Engineering; Epidemiology & Public Health; Life Sciences; Policy, Economics & Labor||Up to $1,000,000||24238|
|NIH National Institute on Alcohol Abuse and Alcoholism (NIAAA)||Notice of Special Interest (NOSI): Availability of Administrative Supplements and Competitive Revision Supplements on COVID-19 within the Mission of NIAAA (NOT-AA-20-011)||
Research is needed to understand the potentially complex relationships between alcohol consumption and COVID-19 related-outcomes to enhance the nation’s response to the current pandemic. The outcomes include overt pathophysiology and the impact of social and policy measures on COVID-19 outcomes. Such studies also will help to lay the groundwork for responding to future public health emergencies. This NOSI encourages applications, in the form of urgent competitive revisions and administrative supplements to existing grants and cooperative agreements, to assess the impact of alcohol as a biological contributor to COVID-19 outcomes, to assess behavioral, social, and economic consequences of the pandemic and to assess the responses that the pandemic has provoked as they relate to alcohol consumption and related outcomes. Applications accepted on a rolling basis
|Behavior & Psychology; Epidemiology & Public Health; Life Sciences; Policy, Economics & Labor||Up to $100,000||24230|
|NIH-National Library of Medicine (NLM)||Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Research on COVID-19 (NOT-LM-20-010)||
The National Library of Medicine (NLM) is offering administrative supplements for research using informatics and data science methods to help address the COVID-19 pandemic in a timely manner. Areas of interest include: 1) Methods for mining clinical data that can be used to identify or predict presence of COVID-19 in biomedical phenotype data, or other relevant topics such as discovery of risks for infection by SARS-Cov- 2 viruses, use of standard terminologies for these viruses in federated health data sets; 2) Public health surveillance methods that mine genomic, viromic, health data, environmental data and/or data from other pertinent sources such as social media, to identify spread and impact of SARS-Cov-2.
|Data Science, AI & Computing; Epidemiology & Public Health||Up to $75,000||24229|
|NIH Office of Behavioral and Social Science Research (OBSSR)||Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences (NOT-OD-20-097)||
This OBSSR NOSI seeks existing longitudinal studies that address key social and behavioral questions related to the COVID-19 pandemic, including adherence to and transmission mitigation from various containment and mitigation efforts; social, behavioral, and economic impacts from these containment and mitigation efforts; and downstream health impacts resulting from these social, behavioral, and economic impacts,including differences in risk and resiliency based on gender, race and ethnicity, socioeconomic status, and other social determinants of health.
|Behavior & Psychology; Community & Social Services; Epidemiology & Public Health; Policy, Economics & Labor||Up to $100,000||24204|
|Henry Wheeler Center for Emerging and Neglected Diseases (CEND)||COVID Catalyst Funding||
The Covid Catalyst fund will provide catalytic seed funding for high-risk projects, as well as catalytic bridge funding for lower risk projects that likely will be successful in attracting government funding long-term. We will be able to fund projects for 3-6 months at a time or until a major milestone is reached. High-risk ideas that turn out to be not feasible should be allowed to fail rapidly so that another approach can be taken. Once the milestone is reached, repeat funding is possible to continue towards implementation.
|Epidemiology & Public Health; Life Sciences||Up to $100K||24185|
|NIDCD||Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19)||
In order to rapidly improve our understanding of the infection of SARS-CoV-2 and of COVID-19, NIDCD is encouraging the submission of applications for supplements to active NIDCD grants to address the pathology, prevention, diagnosis, sequelae, or treatment of COVID-19 directly related to NIDCD’s mission areas of hearing, balance, taste, smell, voice, speech and language. Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.
|Behavior & Psychology; Life Sciences||24136|
|NIH (NCI, NCCIH, NHGRI, NIAID, NICHD, NIDDK, NIEHS, NIGMS, NIMHD, NIBIB, NCATS)||Emergency Competitive Revision to Existing NIH Awards||
The National Institutes of Health (NIH) hereby notify the applicant community that funds may be available for applications based on a presidentially declared disaster under the Stafford Act, a public health emergency declared by the Secretary, HHS, or other local, regional or national disaster. Applications for Emergency Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award. Only applications submitted in response to an Emergency Notice of Special Interest (NOSI) published by an IC will be allowed to apply to this FOA.
|Behavior & Psychology; Community & Social Services; Data Science, AI & Computing; Engineering; Epidemiology & Public Health; Life Sciences; Policy, Economics & Labor||24126|
|NIH-NCATS||Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus||
NCATS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the COVID-19. NCATS is especially interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines. This Notice announces the availability of competitive revisions for investigators and institutions funded through the NIH Microphysiological Systems (MPS) Program; or SBIR/STTR-supported investigators, provided the award involves tissue chips; or microphysiological systems programs from across NIH.
NCATS will accept the submission of applications for Competitive Revisions to active grants on a rolling basis to address only the following research areas of interest:
|Engineering; Life Sciences||24134|
|NIH-NCCIH, NIH-NIA, NIH-NIAAA||Notice of Special Interest (NOSI): Availability of Administrative Supplements and Urgent Competitive Revisions for Research on Stress Management in Relation to Coronavirus Disease 2019 (COVID-19)||
To better understand the impact of stress management strategies in the context of the COVID-19 pandemic, NCCIH is encouraging the submission of applications for Administrative Supplements or Competitive Revisions to active grants. Topics of specific interest for this NOSI include research on stress management strategies, including mind and body approaches, that individuals may engage in remotely to address stressors related to social distancing, as well as to address recovery and recurrence of symptoms during and after COVID-19 infections.
In addition, the National Institute on Aging (NIA) will accept applications for supplements and revisions to NIA-supported projects that fall within the scope of this announcement and are relevant to the mission and strategic priorities of the NIA. Applications are encouraged that address the specific needs and circumstances of midlife and older adults, including, but not limited to, individuals with Mild Cognitive Impairment (MCI), Alzheimer’s disease and Alzheimer’s disease related dementias (AD/ADRD) and their healthcare providers and caregivers.
|Behavior & Psychology; Epidemiology & Public Health; Life Sciences||24137|
|NIH-NCI||Notice of Special Interest (NOSI): National Cancer Institute Announcement Regarding Availability of Urgent Competitive Revision and Administrative Supplements on Coronavirus Disease 2019 (COVID-19)||
The National Cancer Institute (NCI) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and the effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), on cancer, and vice versa. Topics of specific interest to NCI include understanding the basic mechanisms of interaction between SARS-CoV-2 and cancer cells, co-morbidities of cancer and SARS-CoV-2 infection (especially in disparately affected patient populations), and the impacts on treatment and clinical outcomes of SARS-CoV-2 infected persons in the context of cancer. Applications in response to this NOSI must be submitted using the following target funding opportunity announcement or subsequent reissued equivalent.
|NIH-NIBIB||Notice of Special Interest (NOSI): Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)||
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for accelerating the development, translation, and commercialization of technologies to address Coronavirus Disease 2019 (COVID-19). The NIBIB is seeking applications to develop life-saving technologies that can be ready for commercialization within one to two years. Applications in response to this NOSI must be submitted using one of the target opportunities listed in the Notice.
|NIH-NIBIB||Notice of Special Interest (NOSI): Availability of Emergency Competitive Revision and Administrative Supplements on Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)||
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for accelerating the development, translation, and commercialization of technologies to address Coronavirus Disease 2019 (COVID-19). The NIBIB is seeking applications on a rolling basis from current grantees to develop life-saving technologies that can be ready for commercialization within one to two years. Applications in response to this NOSI must be submitted using one of the following target opportunities or subsequently reissued equivalents:
|NIH-NIDDK||Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK||
NIDDK is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19). NIDDK is particularly interested in projects focusing on the direct action of the virus on kidney, gastrointestinal tract function, and the endocrine/metabolic system, and the collection of biosamples that will inform the understanding of renal, gastrointestinal, and endocrine/metabolic sequelae of viral infection. NIDDK will only consider applications that propose projects that may lead to rapid translation and impact in the COVID-19 emergency to be responsive to this NOSI. Submit applications for this initiative using the following funding opportunity announcement (FOA):
|NIH-NIDDK||Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) Related to HIV Comorbidities, Coinfections, and Complications within NIDDK's Mission||
For this funding opportunity announcement, NIDDK is interested in studies to elucidate if COVID-19 might provoke or exacerbate noncommunicable gastrointestinal, liver, kidney/urological and metabolic/endocrine diseases in people with HIV (PWH) or worsen the consequences of viral hepatitis coinfection. Conversely, it is also important to elucidate whether people with HIV (PWH) with CCCs within the mission of NIDDK have different COVID-19 outcomes. Submit applications for this initiative using the following funding opportunity announcement (FOA) or its subsequent reissued equivalent:
|NIH-NIEHS||Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)||
NIEHS is issuing this Notice of Special Interest (NOSI) to address the urgent need for mission-relevant research to understand the impact of environmental exposures on Coronavirus Disease 2019 (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies. Applications should be submitted using the following opportunities:
|Data Science, AI & Computing; Epidemiology & Public Health; Life Sciences||24128|
|NIH-NIMHD, NIH-NIA, NIH-NIMH||Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities||
This NOSI is soliciting research in health disparity populations that seeks to understand: 1) how state and local policies and initiatives mitigate or exacerbate disparities in health services use and health outcomes; 2) the role that community-level protective and resilience factors and interventions have in mitigating the effects of the sector disruptions that the COVID-19 outbreak causes; and 3) how behavioral and/or biological mechanisms may contribute to COVID-19 manifestations. Projects must include a focus on one or more NIH-designated populations that experience health disparities in the United States, which include racial and ethnic minority groups, less privileged socioeconomic status, sexual and gender minorities and underserved rural populations.
In addition to NIMHD, The National Institute of Mental Health (NIMH) will accept and consider support for applications for supplements and revisions to NIMH projects that fall within the scope of this announcement and are relevant to the mission and strategic priorities of the NIMH. Applications to describe the epidemiology of mental disorders and symptoms related to the COVID-19 pandemic are not a high priority; applications to examine how a disrupted workforce may adequately respond/adapt to and maintain services or provide additional care for new or worsening mental health needs where we anticipate health disparities will be most prominent will be seen as a high priority.
The National Institute on Aging (NIA) will accept applications for supplements and revisions to NIA-supported projects that fall within the scope of this announcement and are relevant to the mission and strategic priorities of the NIA. Applications are encouraged that address the specific needs and circumstances of midlife and older adults, including, but not limited to, individuals with Mild Cognitive Impairment (MCI), Alzheimer’s disease and Alzheimer’s disease related dementias (AD/ADRD) and their healthcare providers and caregivers.
|Behavior & Psychology; Community & Social Services; Epidemiology & Public Health; Life Sciences; Policy, Economics & Labor||24133|
|DOD-Defense Health Program||CDMRP PRMRP Technology/Therapeutic Development Award for Emerging Viral Diseases and Respiratory Health||
The PRMRP Technology/Therapeutic Development Award is a product-driven award mechanism intended to provide support for the translation of promising preclinical findings into products for clinical applications in one or more Focus Areas of Emerging Viral Diseases and/or Respiratory Health. Products in development should be responsive to the healthcare needs of military Service members, Veterans, and/or beneficiaries. The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product.
The Principal Investigator (PI) must provide a transition plan showing how the product will progress to the next level of development (e.g., clinical trials, delivery to the military or civilian market) after the completion of the PRMRP award. Proof of concept demonstrating the potential utility of the proposed product, or a prototype/ preliminary version of the proposed product, should already be established.
|Engineering; Epidemiology & Public Health; Life Sciences||up to $4M in total costs||24098|
|DOD-Defense Health Program||CDMRP PRMRP Investigator-Initiated Research Award for Emerging Viral Diseases and Respiratory Health||
The Investigator-Initiated Research Award is designed to support research with the potential to yield highly impactful data that could lead to critical discoveries or major advancements. The application must clearly demonstrate the project’s potential short-term and long-term outcome(s)/product(s) (knowledge and/or materiel) and how they will impact a critical problem or question in the field of research and/or patient care in one or more Focus Areas of Emerging Viral Diseases and/or Respiratory Health.
Research projects may focus on any phase of research from basic laboratory research through translational research, including preclinical studies in animal models and human subjects, as well as correlative studies associated with an existing clinical trial. The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.
|Epidemiology & Public Health; Life Sciences||up to $2M in total costs||24097|
|DOD-Defense Health Program||CDMRP PRMRP Clinical Trial Award for Emerging Viral Diseases and Respiratory Health Department of Defense||
The PRMRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact in one or more of the Focus Areas of Emerging Viral Diseases and Respiratory Health. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, Phase 0), to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.
Funding from this award mechanism must support a clinical trial, cannot be used for animal studies, and must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.
|Engineering; Epidemiology & Public Health; Life Sciences||up to $30M in total costs, shared among five awards.||24099|
|Google Cloud research credits||
Google invites applications to leverage its computing capabilities and infrastructure to study potential therapies and vaccines, track critical data, and identify new ways to combat COVID-19. Google Cloud research credits can advance your research by giving you access to computing power that will make the next big thing possible.
|Data Science, AI & Computing; Engineering; Epidemiology & Public Health; Life Sciences||24105|
|U.S.-Israel Binational Science Foundation||Call for Proposals in Joint NSF-BSF Programs Dealing with the Coronavirus Disease||
The U.S.-Israel Binational Science Foundation (BSF) is accepting applications dealing with the Coronavirus Disease in all the active NSF-BSF programs. Research projects in Biology (DEB, IOS, MCB), the Geosciences (Earth Sciences, Ocean Sciences, Atmospheric and Geospace), Engineering (CBET, ECCS, CMMI, EEC, EFMA, IIP) Materials, Physics divisions are approved for submission. The BSF is waiting for approval from other NSF units, and expects that submission to this RAPID program in more fields will be possible soon. Submission of COVID-19 related proposals to all regular NSF-BSF programs is, of course, still possible.
|Engineering; Life Sciences||24107|
|DOD-Air Force||Commercial Solution Opening (CSO) COVID-19 Response (FA3002-20-S-0002)||
The Department of the Air Force Acquisition COVID-19 Task Force (DAF ACT) has established a Commercial Solution Opening (CSO) seeking innovative, commercial technologies that propose new solutions and/or potentially new capabilities that fulfill requirements, close capability gaps, or provide potential technological advancements in support of the DAF ACT mission to provide relief, resilience, recovery, and stability to the nation in response to the COVID-19 pandemic. Of the seven mission focus areas, the initial Area of Interest is expected to be "Combating the Spread" (i.e. predictive analytics, next hotspot, threat to current activities, decision support, etc.). The CSO, a vehicle for future solicitations, is open to defense contractors, large and small businesses, and research institutions, with a focus on non-traditional organizations that do not typically work with the government. Rolling review of submissions through 9/30/2020
|Behavior & Psychology; Community & Social Services; Data Science, AI & Computing; Engineering; Epidemiology & Public Health; Policy, Economics & Labor||24095|
|Joint European Disruptive Initiative (JEDI)||Billion Molecules against COVID-19 Grand Challenge||
The Joint European Disruptive Initiative is launching the Billion Molecules against COVID-19 Grand Challenge, with grand prizes of up to 2 million Euros. The objective: to screen billions of molecules with blocking interactions relevant to SARS-CoV-2, and fast-track the route to a therapeutic treatment. The current major health crisis has highlighted the need for strong anticipation, interdisciplinarity and massive agility. This is the first-ever DARPA-type challenge in Europe at the intersection of epidemiology, high performance computing, molecular biology and artificial intelligence. The Grand Challenge will be open to comments and input from the wider Scientific community between April 7 and April 14, after which it is expected to be open for eight weeks.
|Data Science, AI & Computing; Epidemiology & Public Health; Life Sciences||Up to 2 million Euros||24094|
|NIH-NIAID||Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)||
In this call for revisions to funded grants, NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.
|NIH-NIGMS||Notice of Special Interest (NOSI) Regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (NOT-AI-20-030)||
NIGMS will accept the submission of applications for Competitive Revisions to active grants to address only the following research areas of interest:
|Omidyar Network||COVID-19 Economic Response Advocacy Fund||
This fund intends to infuse funding into national, state, and local advocacy and organizing efforts aimed at passing economic stimulus to address the immediate toll of the COVID-19 pandemic on working people while reshaping economic structures to ensure they are less vulnerable in the future. The call is focused on direct advocacy efforts to achieve policy or regulatory solutions at the national, state, or local level that protect and assist working people and small businesses now and establish new precedents that improve worker power and well-being in the future; digital organizing that reconfigures campaigns that can no longer be carried out in person due to the virus; strategic communications, coordination, and narrative development efforts that bring like-minded organizations together to create a louder, more unified voice calling for policy and regulatory changes at the national, state, or local level that result in a stronger economy.
|Policy, Economics & Labor||24096|
|DOD Joint Acquisition Task Force (JATF)||COVID-19 Request for Information (RFI)||
DoD JATF is seeking input to shape its COVID-19 funding decisions focused on the accelerated ramp-up of production capacity for critical healthcare products such as masks, ventilators, test kits, and vaccines. JATF Focus Areas: 1) Combating Spread, 2) Welfare of Citizens, 3) Readiness, 4) Logistics, 5) Industrial base impacts, 6) Medical, 7) Other
|Data Science, AI & Computing; Engineering; Epidemiology & Public Health; Policy, Economics & Labor||24075|
|DOD-Army||Army Futures Command's (AFC) Army Applications Laboratory (AAL) Request for Ideas||
The Army Futures Command’s (AFC) Army Applications Laboratory (AAL) has expressed significant interest in new technologies to support the Army’s COVID-19 response including innovative medical equipment, therapeutics, diagnostics, and vaccines. AAL has set up a webpage for organizations to schedule a brief phone call to discuss their ideas for technologies that support diagnosis, care, and the protection of healthcare providers, active duty service members, their families, and communities from COVID-19.
|Engineering; Epidemiology & Public Health; Life Sciences||24079|
|Emergent Ventures||Emergent Ventures Fast Funding for COVID-19 Science||
If you are a scientist at an academic institution currently working on a COVID-19 related project and in need of funding, the Emergent Ventures project at the Mercatus Center invites you to apply for a Fast Grant. A Fast Grant must be used solely to expedite COVID-19-related science, but the area of research is open. Fast grants are $10k to $500k and decisions are made in under 48 hours.
|Behavior & Psychology; Community & Social Services; Data Science, AI & Computing; Engineering; Epidemiology & Public Health; Humanities; Life Sciences; Policy, Economics & Labor||Up to $500,000||24074|
|HHS-AHRQ||Notice of Intent: New Funding Opportunity Announcement to Support Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19||
AHRQ intends to publish a new funding opportunity announcement in April using the R01 mechanism to support novel, high-impact studies evaluating health system and healthcare professional responsiveness to COVID-19. AHRQ will look to fund critical research focused on evaluating topics such as innovations and challenges encountered in the rapid expansion of telemedicine in response to COVID-19; effects on quality, safety, and value of health system response to COVID-19; and the role of primary care practices and professionals during the COVID-19 epidemic. AHRQ is particularly interested in understanding how digital health innovations contributed to health system and healthcare professional innovation and challenges and solutions to meeting the needs of vulnerable populations including older adults, people living with multiple chronic conditions, rural communities, and uninsured and underinsured populations.
|Behavior & Psychology; Community & Social Services; Data Science, AI & Computing; Epidemiology & Public Health; Policy, Economics & Labor||24070|
|HHS-AHRQ||Notice of Intent: Revision Supplements to Existing AHRQ Grants and Cooperative Agreements to Address Health System Responsiveness to COVID-19||
AHRQ intends to publish a new funding notice in April allowing requests for urgent revision supplements to existing AHRQ grants and cooperative agreements to address health system responsiveness to COVID-19.
|Behavior & Psychology; Community & Social Services; Epidemiology & Public Health; Policy, Economics & Labor||24069|
|HHS-BARDA||CoronaWatch/TechWatch Medical Countermeasures||
To enable a rapid-response to the COVID-19 outbreak, BARDA has repurposed its existing TechWatch program to focus on COVID-19 medical countermeasures. These CoronaWatch submissions and meetings aim to give innovators and innovative companies a government-wide platform to discuss their ideas with U.S. government experts, and seek partnership opportunities with a wide range of potential federal partners. BARDA is particularly interested in products and technologies that have progressed into or beyond non-clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products or technologies relevant to addressing this outbreak are sought.
|Engineering; Life Sciences||24072|
|NASA||Making Innovative Use of NASA Satellite Data to Address Environmental, Economic, and/or Societal Impacts of the COVID-19 pandemic||
Program Element A.28 "Rapid Response and Novel Research in Earth Science" (RRNES) of Research Opportunities in Space and Earth Sciences (ROSES) 2020 provides an opportunity to propose investigations making innovative use of NASA satellite data to address regional-to-global environmental, economic, and/or societal impacts of the COVID-19 pandemic. Potential proposals may address R&A-related topics more fundamental in underlying physical and/or biological sciences (including possible connections to socioeconomic activities) and/or ASP-related topics characterizing impacts of decisions or efforts to inform decision makers on regional-to-global levels in their responses to mitigate the impacts of the disease. While proposed studies must use NASA satellite data and information products as a primary source of information and research tools, they may also utilize remote sensing data and products from government agencies, international, or commercial sources. Studies utilizing Artificial Intelligence (AI) techniques including Machine Learning (ML) and Deep Learning (DL) are encouraged. Rolling deadline.
|Data Science, AI & Computing; Engineering||24076|
|NEH||Office of Digital Humanities COVID Response: Virtual Visits||
The Office of Digital Humanities at the National Endowment for the Humanities wants to let university instructors know that we are available to visit your classroom, library, or DH center virtually. We are offering 15-20 minute visits such as the following:
|Novartis||COVID-19 Response Fund||
In response to the COVID-19 pandemic, the Novartis US Foundation has established the US COVID-19 Community Response Fund to support local initiatives and communities in the US impacted by the outbreak. The fund will provide up to USD $5 million total over a one-year period for immediate response and recovery efforts related to the pandemic. Programs must support one or more of the three stated objectives: Strengthening local and national healthcare infrastructure to meet increased demand and protect frontline health workers, establishing digital platforms for COVID-19 related data collection, remote delivery of healthcare and effective dissemination of important public health information, or creating or enhancing new community health programs specific to the pandemic response. R&D efforts related to COVID-19 are not eligible.
|Data Science, AI & Computing; Epidemiology & Public Health||$100,000-$250,000||24068|
|Elevate Prize Foundation||Elevate Prize||
Guided by the UN's Sustainable Development Goals and in partnership with MIT Solve, the Elevate Prize competition will award up to $5 million annually to ten "global heroes" who are working to address an urgent problem, including emerging pandemics and health security threats such as COVID-19. Awardees will receive at least $300,000 over two years to advance their efforts to change the world, with the potential for additional financial support, as well as access to management and development assistance, mentorship and counseling, educational training, and a platform through which they can amplify and scale their work. In response to the COVID-19 pandemic, MIT Solve has launched an additional challenge — the Health Security & Pandemics Challenge — and will award one of the ten Elevate Prizes to a "Solver" team that emerges from the competition.
|Community & Social Services; Data Science, AI & Computing; Engineering; Epidemiology & Public Health; Life Sciences; Policy, Economics & Labor||Minimum of $300K prize||24040|
|Allen Institute for AI||COVID-19 Open Research Dataset Challenge (CORD-19)||
This is a call to the world's artificial intelligence experts to develop text and data mining tools that can help the medical community develop answers to high priority scientific questions using the new COVID-19 Open Research Dataset (CORD-19). CORD-19 is a resource of over 45,000 scholarly articles, including over 33,000 with full text, about COVID-19, SARS-CoV-2, and related coronaviruses. This freely available dataset is provided to the global research community to apply recent advances in natural language processing and other AI techniques to generate new insights in support of the ongoing fight against this infectious disease.
|Data Science, AI & Computing||$1,000 per task award||24001|
|DOC-NIST||Manufacturing USA National Emergency Assistance Program||
Projects should focus on responding to the COVID-19 pandemic. Projects may include medical countermeasures; non-medical countermeasures; leveraging institute capabilities to strengthen state and community resilience; grants to companies and technical support to accelerate productions of critical materials, equipment, and supplies; creation of additional production facilities; technology roadmapping for pandemic response and recovery; reshoring the manufacture of critical conventional drugs and ensuring supply chain for critical materials related to pandemic response; or workforce development and training for a skilled advanced manufacturing workforce.
|Community & Social Services; Epidemiology & Public Health||Up to $10,000,000||24007|
|DOE-Office of Science||RAPID REQUEST: Coronavirus Disease 2019 (COVID-19) Dear Colleague Letter||
DOE is asking for input on COVID-19 rapid research response involving DOE user facilities and infrastructure.
|Data Science, AI & Computing; Engineering; Life Sciences||24034|
|Gates Foundation, Wellcome Trust, Mastercard, CZI||COVID-19 Therapeutics Accelerator||
The Bill & Melinda Gates Foundation, along with Wellcome, Mastercard, and CZI are leading the $145 million COVID-19 Therapeutics Accelerator. The accelerator is working in tandem with the World Health Organization, national governments, business sectors and organizations to deliver end-to-end results, ‘from drug pipeline development through manufacturing and scale-up’; with a focus on minimizing the ‘financial and technical risk for academia, biotech, and pharmaceutical companies, while also ensuring that these products are accessible and affordable to people in low-resource settings’. The COVID-19 Therapeutics Accelerator will not be conducting a traditional funding call. To learn more about the funding process, or how to invest in the accelerator, contact firstname.lastname@example.org.
|Epidemiology & Public Health; Life Sciences||No funding limitations||24004|
|Ginkgo Bioworks||Free Access to Ginkgo Platform||
Ginkgo is offering: $25M of no-cost foundry work towards projects that can use Ginkgo’s platform to accelerate development of point of care diagnostics, vaccines, or therapeutics; as well as connection to sources of funding from private and public sources. Gingko is coordinating with entrepreneurs including Sam Altman and others on private funding efforts. Gingko also promises rapid sharing of R&D information among the community of academics and companies working on solutions. If you are currently a company or academic lab that is developing a diagnostic, drug, or vaccine and are interested in leveraging Ginkgo’s infrastructure at no cost email email@example.com.
|Data Science, AI & Computing; Epidemiology & Public Health; Life Sciences||In-Kind||24008|
|HHS-BARDA||Broad Agency Announcement||
Biomedical Advanced Research and Development Authority (BARDA) is investing in an array of medical countermeasures to diagnose, treat, or protect against the 2019 novel coronavirus under the BARDA Broad Agency Announcement (BAA-18-100-SOL-00003). COVID-19 response related Areas of Interest includes: Diagnostic assay for human coronavirus using existing FDA-cleared platforms; Point-of-care diagnostic assay for detection of SARS-CoV-2 virus, Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection), COVID-19 Vaccine, COVID-19 Therapeutics, Immunomodulators or therapeutics targeting lung repair, Pre-exposure and post-exposure prophylaxis, Respiratory protective devices, Ventilators, and Advanced Manufacturing Technologies.
|Engineering; Life Sciences||24030|
|HHS-BARDA||BARDA's Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement: Molecular Diagnostics and Nonclinical Assays||
Biomedical Advanced Research and Development Authority (BARDA) is looking for: Molecular diagnostic assay for SARS-CoV-2 virus on existing FDA-cleared platform, Point-of-care diagnostic assay for detection of SARS-CoV-2 virus, Diagnostic assay for detection of COVID-19 disease, Nonclinical model development and screening for SARS-CoV-2 virus, Alternate vaccine delivery/administration and adjuvants, and Advanced manufacturing technologies. Rolling deadline.
|Engineering; Life Sciences||24031|
|Mozilla Open Source Support Program (MOSS)||Open Source Support Awards||
Mozilla announced a COVID-19 Solutions Fund as part of the Mozilla Open Source Support Program (MOSS). Through this fund, we will provide awards of up to $50,000 each to open source technology projects which are responding to the COVID-19 pandemic in some way. As part of the COVID-19 Solutions Fund, we will accept applications that are hardware (e.g., an open source ventilator), software (e.g., a platform that connects hospitals with people who have 3D printers who can print parts for that open source ventilator), as well as software that solves for secondary effects of COVID-19 (e.g., a browser plugin that combats COVID related misinformation).
|Data Science, AI & Computing; Engineering||Up to $50,000||24010|
|NIH-NIA||Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)||
NIA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19). The mission of NIA is to support and conduct genetic, biological, clinical, behavioral, social, and economic research on aging. This NOSI supports mission critical areas of research for NIA as they relate to the COVID-19 pandemic.
|Behavior & Psychology; Epidemiology & Public Health||24006|
|NSF||Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19)||
The Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities.
|Data Science, AI & Computing||24033|
|NSF||Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19)||
National Science Foundation (NSF) is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.
|Behavior & Psychology; Community & Social Services; Data Science, AI & Computing; Engineering; Epidemiology & Public Health; Humanities; Life Sciences; Policy, Economics & Labor; Instruction||24032|
|OSTP DOE IBM||COVID-19 High Performance Computing Consortium||
The COVID-19 High Performance Computing Consortium helps aggregate computing capabilities from the world's most powerful and advanced computers to help COVID-19 researchers execute complex computational research programs to help fight the virus. Researchers seeking to access the Consortium’s resources should submit a simple project proposal that will be reviewed for potential impact, computational feasibility, overall resource requirements and timeline.
|Behavior & Psychology; Data Science, AI & Computing; Engineering; Epidemiology & Public Health; Life Sciences||24035|
|Pulitzer Center on Crisis Reporting||Coronavirus News Collaboration Challenge||
The Pulitzer Center on Crisis Reporting, a non-profit organization that supports independent global journalism, is seeking proposals that develop innovative approaches to reporting on the novel coronavirus crisis using collaboration among journalists and newsrooms across state lines or national borders. This opportunity is open to all newsrooms and independent journalists in the United States and abroad.
|Community & Social Services; Policy, Economics & Labor||No funding limitations||24011|
|Amazon Web Services||AWS Diagnostic Development Initiative (DDI)||
The initiative supports AWS customers who are working to bring better, more accurate diagnostic solutions to market faster. The emphasis initially will be on COVID-19.
|Data Science, AI & Computing||23943|
|NIH-NCATS||Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19) (NOT-TR-20-012)||
NCATS is particularly interested in projects that repurpose existing drugs or biologics that have already begun or completed a Phase I clinical trial. Deadline: Varies by program, see the NOSI.
|NIH-NCATS||Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need (NOT-TR-20-011)||
NCATS is particularly interested in projects focusing on the use of informatics solutions to diagnose cases and the use of CTSA-supported core resources to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines. Deadline: Varies by program, see the NOSI.
|NIH-NHLBI||Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) (NOT-HL-20-757)||
Topics of specific interest to NHLBI include host response, associations with heart, lung, and blood diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals.
|NIH-NIAID||Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed)||
This initiative will support development of new or improved therapeutics for emerging viral pathogens of public health concern. Note that this FOA will support development of a candidate therapeutic against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19.
|NIH-NIAID||Collaborative Cross (CC) Mouse Model Generation and Discovery of Immunoregulatory Mechanisms (R21 Clinical Trial Not Allowed)||
NIAID has funded the use and further development of the CC mouse lines for immunology and infectious disease research, including SARS-CoV.
If your proposed research on SARS-CoV-2/COVID-2019 is within the scope of your current NIAID grant, an administrative supplement is your best option to obtain additional funding.
|NIH-NIAID||Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-AI-20-031)||
NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.
|NIH-NIAID & NIGMS||Notice of Special Interest (NOSI) Regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV) (NOT-AI-20-030)||
NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against 2019-nCoV. NIGMS is specifically interested in incorporation of data from the 2019-nCoV into ongoing research efforts to develop predictive models for the spread of Coronaviruses and related pathogens. Deadline: 2/6/2021 4/7/2020. NOTE: As of 4/8/2020, this NOSI (NOT-AI-20-030), will be rescinded (NOT-AI-20-040) and replaced by NOT-AI-20-034 for NIAID competitive revisions and NOT-GM-20-025 for NIGMS competitive revisions.
|NIH-NIDA||Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (NOT-DA-20-047)||
NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders